Next Article in Journal
Interactive Association of Drugs Binding to Human Serum Albumin
Next Article in Special Issue
Role of VEGF-A and Its Receptors in Sporadic and MEN2-Associated Pheochromocytoma
Previous Article in Journal
Association between Single Nucleotide Polymorphism rs1044925 and the Risk of Coronary Artery Disease and Ischemic Stroke
Previous Article in Special Issue
Risk-Association of Five SNPs in TOX3/LOC643714 with Breast Cancer in Southern China
Int. J. Mol. Sci. 2014, 15(3), 3560-3579; doi:10.3390/ijms15033560
Article

Activation of VCAM-1 and Its Associated Molecule CD44 Leads to Increased Malignant Potential of Breast Cancer Cells

1,†
, 1,†
, 1
, 1
, 2
, 3,4,5
 and 1,5,*
Received: 28 December 2013; in revised form: 30 January 2014 / Accepted: 14 February 2014 / Published: 27 February 2014
(This article belongs to the Special Issue Molecular Bases of Cancer Research)
View Full-Text   |   Download PDF [802 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: VCAM-1 (CD106), a transmembrane glycoprotein, was first reported to play an important role in leukocyte adhesion, leukocyte transendothelial migration and cell activation by binding to integrin VLA-1 (α4β1). In the present study, we observed that VCAM-1 expression can be induced in many breast cancer epithelial cells by cytokine stimulation in vitro and its up-regulation directly correlated with advanced clinical breast cancer stage. We found that VCAM-1 over-expression in the NMuMG breast epithelial cells controls the epithelial and mesenchymal transition (EMT) program to increase cell motility rates and promote chemoresistance to doxorubicin and cisplatin in vitro. Conversely, in the established MDAMB231 metastatic breast cancer cell line, we confirmed that knockdown of endogenous VCAM-1 expression reduced cell proliferation and inhibited TGFβ1 or IL-6 mediated cell migration, and increased chemosensitivity. Furthermore, we demonstrated that knockdown of endogenous VCAM-1 expression in MDAMB231 cells reduced tumor formation in a SCID xenograft mouse model. Signaling studies showed that VCAM-1 physically associates with CD44 and enhances CD44 and ABCG2 expression. Our findings uncover the possible mechanism of VCAM-1 activation facilitating breast cancer progression, and suggest that targeting VCAM-1 is an attractive strategy for therapeutic intervention.
Keywords: VCAM-1; breast cancer progression; EMT; metastasis; chemoresistance VCAM-1; breast cancer progression; EMT; metastasis; chemoresistance
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Wang, P.-C.; Weng, C.-C.; Hou, Y.-S.; Jian, S.-F.; Fang, K.-T.; Hou, M.-F.; Cheng, K.-H. Activation of VCAM-1 and Its Associated Molecule CD44 Leads to Increased Malignant Potential of Breast Cancer Cells. Int. J. Mol. Sci. 2014, 15, 3560-3579.

AMA Style

Wang P-C, Weng C-C, Hou Y-S, Jian S-F, Fang K-T, Hou M-F, Cheng K-H. Activation of VCAM-1 and Its Associated Molecule CD44 Leads to Increased Malignant Potential of Breast Cancer Cells. International Journal of Molecular Sciences. 2014; 15(3):3560-3579.

Chicago/Turabian Style

Wang, Pei-Chen; Weng, Ching-Chieh; Hou, You-Syuan; Jian, Shu-Fang; Fang, Kuan-Te; Hou, Ming-Feng; Cheng, Kuang-Hung. 2014. "Activation of VCAM-1 and Its Associated Molecule CD44 Leads to Increased Malignant Potential of Breast Cancer Cells." Int. J. Mol. Sci. 15, no. 3: 3560-3579.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert